FibroGen Reports Second Quarter 2017 Financial Results
07 août 2017 16h38 HE
|
FibroGen, Inc.
Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, Aug. 07, 2017 ...
FibroGen Reports Fiscal 2016 Financial Results
01 mars 2017 16h02 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
02 août 2016 20h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
08 juil. 2016 04h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million...
FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
06 juin 2016 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...
FibroGen Reports Financial Results for the First Quarter of 2016
09 mai 2016 16h02 HE
|
FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
11 mars 2016 08h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...
MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF
09 oct. 2015 06h00 HE
|
MediciNova, Inc.
LA JOLLA, Calif., Oct. 09, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
CPF Celebrates Historic Year of Progress in Pulmonary Fibrosis
30 déc. 2014 14h05 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) played an important role in much of the year's successes in Pulmonary Fibrosis (PF), helping to make...
CPF Applauds Two FDA Approvals Announced Today for First Drugs for Idiopathic Pulmonary Fibrosis
15 oct. 2014 18h02 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, CALIF., Oct. 15, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) applauds the two U.S. Food and Drug Administration (FDA) approvals announced today for Idiopathic...